PYY and Satiety: The Gut Hormone That Curbs Appetite

The clinical context

Understanding how the body naturally signals fullness is the foundation of modern appetite research. Among the gut's satiety hormones, peptide YY (PYY) stands out both for how reliably it curbs appetite and for the clue it offers about why weight-loss surgery works. This use case is educational and describes an area of active research and clinician-managed care.

What PYY is

Peptide YY is a 36-amino-acid hormone released from L-cells lining the ileum and colon — the lower small intestine and large intestine. It is the body's own hormone, not a marketed drug. PYY is secreted after a meal, in proportion to the calories and nutrients consumed, making it a faithful report of "food has arrived."

Its most active form is PYY3-36, a shortened version generated after release. PYY3-36 acts on the Y2 receptor to reduce appetite, signaling to the appetite-regulation centers of the brain — including via the gut-brain axis — that it is time to stop eating. PYY belongs to the same "PP-fold" family as neuropeptide Y and pancreatic polypeptide, but where NPY drives hunger in the brain, PYY from the gut promotes fullness.

The bariatric surgery clue

One of the most striking facts about PYY is what happens after bariatric (weight-loss) surgery. Procedures such as gastric bypass produce an exaggerated rise in PYY (and other gut hormones like GLP-1) after meals. This surge is thought to be one reason bariatric surgery reduces hunger so effectively — far more than would be expected from restriction of stomach size alone.

That observation reframed obesity science. It suggested that the durable appetite reduction after surgery is substantially hormonal, not merely mechanical, and it pointed directly to gut satiety hormones as targets for drugs that might reproduce some of surgery's benefits without an operation.

PYY in drug research

Because raising PYY signaling reduces appetite, PYY is an active target for anti-obesity drugs. A recurring strategy is to combine PYY-based agents with GLP-1 receptor activation, pairing two complementary satiety mechanisms — much as the field has embraced combination approaches elsewhere (see oxyntomodulin for weight loss).

Delivering PYY as a drug has practical challenges, including how to dose it without provoking nausea and how to sustain its effect, which is why development has focused on engineered analogs and co-agonist combinations. This mirrors how the approved GLP-1 medicine semaglutide and the amylin analog cagrilintide are being studied in combinations to press multiple satiety levers at once. PYY-based analogs specifically remain investigational.

Where it fits

PYY itself is a natural hormone and is not sold as a medicine. Its value here is as a key to understanding appetite: it explains part of why we feel full after eating, offers a biological account of why bariatric surgery curbs hunger, and defines a target that drug developers continue to pursue for appetite control.

The bottom line

PYY is a post-meal gut hormone that signals fullness through the Y2 receptor, surges dramatically after bariatric surgery, and sits at the center of anti-obesity drug research — usually in combination with GLP-1. It is the body's own satiety signal, not a product, and PYY-based drugs remain investigational. Understanding it clarifies both normal appetite and the logic behind the newest weight-management therapies.

This use case is educational and not medical advice. PYY is a natural hormone; PYY-based drugs are investigational, and weight-management therapy requires clinical supervision.